This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Sep 2026 quarter revenue up 197% to Rs 562.45 lakh from Rs 189.10 lakh a year ago
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone revenue from operations for the quarter ended 30 September 2026 was Rs 562.45 lakh versus Rs 189.10 lakh in the year-ago quarter. Profit after tax was Rs 3.03 lakh, below the year-ago quarter. The operating margin before interest, depreciation and tax fell year on year. For the standalone half year ended 30 September 2026, revenue was Rs 1,241.33 lakh, profit after tax was Rs 18.46 lakh and operating cash flow was negative.
Strong sales growth may support sentiment, but weaker margins, lower profit after tax and negative operating cash flow could limit upside.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹5.62 Cr | ₹4.89 Cr | +15.0% |
| Operating profit | −₹0.11 Cr | −₹0.02 Cr | loss widened |
| Profit after tax | ₹0.03 Cr | ₹0.07 Cr | −57.6% |
| EBITDA margin | -1.4% | 0.3% | −1.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.